|
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940 |
|
| |||||||||||||||||||||||||||||
|
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly. | |||
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number. | SEC 1474 (9-02) |
1. Title of Derivative Security (Instr. 3) |
2. Conversion or Exercise Price of Derivative Security | 3. Transaction Date (Month/Day/Year) | 3A. Deemed Execution Date, if any (Month/Day/Year) | 4. Transaction Code (Instr. 8) |
5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5) |
6. Date Exercisable and Expiration Date (Month/Day/Year) |
7. Title and Amount of Underlying Securities (Instr. 3 and 4) |
8. Price of Derivative Security (Instr. 5) |
9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) |
10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) |
11. Nature of Indirect Beneficial Ownership (Instr. 4) |
||||
Code | V | (A) | (D) | Date Exercisable | Expiration Date | Title | Amount or Number of Shares | ||||||||
Stock Option (Right to Buy) | $ 39 | 12/02/2014 | A | 30,000 | (4) | 12/02/2024 | Common Stock | 30,000 | (3) | 30,000 | D |
Reporting Owner Name / Address | Relationships | |||
Director | 10% Owner | Officer | Other | |
Wilson Kenneth H C/O AMAG PHARMACEUTICALS, INC. 1100 WINTER STREET WALTHAM, MA 02451 |
SVP, Sales and Marketing |
Nancy R. Smith, attorney-in-fact for Reporting Person | 12/04/2014 | |
**Signature of Reporting Person | Date |
* | If the form is filed by more than one reporting person, see Instruction 4(b)(v). |
** | Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a). |
(1) | These shares of common stock are issuable by AMAG Pharmaceuticals, Inc. (the "Company") pursuant to a grant of restricted stock units by the Company pursuant to and subject to the Lumara Health Inc. Amended and Restated 2013 Incentive Compensation Plan (the "Lumara Equity Plan"). This grant of restricted stock units by the Company vests in four equal installments with the first annual installment vesting on November 13, 2015. |
(2) | Each restricted stock unit represents a contingent right to receive one share of AMAG Pharmaceuticals, Inc. common stock. |
(3) | Not applicable. |
(4) | This option to purchase shares of the Company is made pursuant to and subject to the Lumara Equity Plan, and vests and becomes exercisable in four equal annual installments with the first annual installment vesting on November 13, 2015. |
Remarks: Mr Wilson's full title is Senior Vice President of Sales and Marketing, Lumara Health Division and President, Lumara Health Division. |